References
- Abruzzese E, Trawinska MM, Coletta A et al. (2009) Peptide-vaccine treatment associated with TKI therapy in patients with CML is able to induce immunologic, cytogenetic and molecular responses: a single center experience with long-term follow up. Blood 114:2185.
https://doi.org/10.1182/blood.V114.22.2185.2185 - Barbarin A, Abdallah M, Lefèvre L et al. (2020) Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib. Sci Rep 10:3245.
https://doi.org/10.1038/s41598-020-60195-z - Basbous S, Levescot A, Piccirilli N et al. (2016) The Rho–ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia. J Pathol 240:262–268.
https://doi.org/10.1002/path.4779 - Bassiri H, Das R, Guan P et al. (2014) iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo. Cancer Immunol Res 2:59–69.
https://doi.org/10.1158/2326-6066.CIR-13-0104 - Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300.
https://doi.org/10.1111/J.2517-6161.1995.tb02031.x - Bocchia M, Gentili S, Abruzzese E et al. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365:657–662.
https://doi.org/10.1016/s0140-6736(05)17945-8 - Braga AGO, Barbosa Pagnano KB, Campioni MDP et al. (2024) Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia. Hematol Transfus Cell Ther 46:268–272.
https://doi.org/10.1016/j.htct.2023.06.001 - Burchert A, Saussele S, Michel C et al. (2022) Efficacy of ropeginterferon Alpha 2b in inducing treatment free remission in chronic myeloid leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group. Blood 140(Suppl. 1):1501–1503.
https://doi.org/10.1182/blood-2022-169324 - Cathcart K, Pinilla-Ibarz J, Korontsvit T et al. (2004) A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103:1037–1042.
https://doi.org/10.1182/BLOOD-2003-03-0954 - Cayssials E, Jacomet F, Piccirilli N et al. (2019) Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol 186:54–59.
https://doi.org/10.1111/BJH.15858 - Chang MC, Cheng HI, Hsu K et al. (2019) NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Front Immunol 9:3152.
https://doi.org/10.3389/fimmu.2018.03152 - Clark RE, Christmas SE (2001) BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leuk Lymphoma 42:871–880.
https://doi.org/10.3109/10428190109097706 - Clark RE, Dodi IA, Hill SC et al. (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98:2887–2893.
https://doi.org/10.1182/blood.V98.10.2887 - Collins RH Jr, Shpilberg O, Drobyski WR et al. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–444.
https://doi.org/10.1200/JCO.1997.15.2.433 - Decroos A, Meddour S, Demoy M et al. (2024) The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy. Front Immunol 15:1473139.
https://doi.org/10.3389/fimmu.2024.1473139 - Dhodapkar MV, Geller MD, Chang DH et al. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667–1676.
https://doi.org/10.1084/jem.20021650 - Dou N, Hu Q, Li L et al. (2020) USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2. Int J Biol Sci 16:1648–1657.
https://doi.org/10.7150/ijbs.43117 - Fassoni AC, Yong ASM, Clark RE et al (2025) Predicting treatment-free remission in chronic myeloid leukemia patients using an integrated model of tumor-immune dynamics. npj Syst Biol Appl 2025 111 11:1–13.
https://doi.org/10.1038/s41540-025-00598-8 - Fujii S, Shimizu K, Okamoto Y et al. (2013) NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol 4:409.
https://doi.org/10.3389/fimmu.2013.00409 - Fujioka Y, Sugiyama D, Matsumura I et al. (2021) Regulatory T cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia. Cancers 13:5904.
https://doi.org/10.3390/cancers13235904 - Garcia CAB, Binelli LS, Palma LC et al. (2024) Immune content of mature and licensed cytotoxic cells is associated with treatment-free remission in chronic myeloid leukemia. Blood 144(Suppl. 1):1756.
https://doi.org/10.1182/blood-2024-208109 - Giallongo C, Parrinello N, Tibullo D et al. (2014) Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One 9:e101848.
https://doi.org/10.1371/journal.pone.0101848 - Giannopoulos K, Dmoszynska A, Rolinski J et al. (2009) Identification of RHAMM-derived CD8+ restricted, heteroclitical, cryptic epitope R9Y as a promising target for immunotherapy of chronic lymphocytic leukemia. Blood 114:3034.
https://doi.org/10.1182/blood.v114.22.3034.3034 - Greiner J, Schmitt M (2008) Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol 80:461–468.
https://doi.org/10.1111/J.1600-0609.2008.01053.x - Gross DA, Graff-Dubois S, Opolon P et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433.
https://doi.org/10.1172/JCI19418 - Guglielmi C, Arcese W, Dazzi F et al. (2002) Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100:397–405.
https://doi.org/10.1182/blood.v100.2.397 - Hermans IF, Silk JD, Gileadi U et al. (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171:5140–5147.
https://doi.org/10.4049/jimmunol.171.10.5140 - Huff CA, Fuchs EJ, Smith BD et al. (2006) Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 12:414–421.
https://doi.org/10.1016/j.bbmt.2005.11.520 - Hughes A, Clarson J, Tang C et al. (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129:1166–1176.
https://doi.org/10.1182/blood-2016-10-745992 - Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:17–23.
https://doi.org/10.1182/blood-2016-01-694265 - Huuhtanen J, Adnan-Awad S, Theodoropoulos J et al. (2024) Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia 38:109–125.
https://doi.org/10.1038/s41375-023-02074-w - Hu W, Wei H, Li K et al. (2017) Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. Cell Prolif 50:e12343.
https://doi.org/10.1111/cpr.12343 - Ilander M, Olsson-Strömberg U, Schlums H et al. (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108–1116.
https://doi.org/10.1038/leu.2016.360 - Irani YD, Hughes A, Clarson J et al. (2020) Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol 191:433–441.
https://doi.org/10.1111/bjh.16718 - Jacomet F, Cayssials E, Barbarin A et al. (2017) The hypothesis of the human iNKT/Innate CD8(+) T-cell axis applied to cancer: evidence for a deficiency in chronic myeloid leukemia. Front Immunol 7:688.
https://doi.org/10.3389/fimmu.2016.00688 - Kanojia D, Garg M, Saini S et al. (2010) Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leuk Res 4:858–863.
https://doi.org/10.1016/j.leukres.2010.01.017 - Kjaer L, Skov V, Andersen MT et al. (2019) Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against cancer qPCR assay. Eur J Haematol 103:26–34.
https://doi.org/10.1111/ejh.13238 - Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050.
https://doi.org/10.1182/blood.v86.5.2041.bloodjournal8652041 - Kong J, Qin YZ, Zhao XS et al. (2021) Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Ann Hematol 100:2557–2566.
https://doi.org/10.1007/S00277-021-04606-9 - Kreutzman A, Yadav B, Brummendorf TH et al. (2019) Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology 8:e1638210 (13 pages).
https://doi.org/10.1080/2162402X.2019.1638210 - Kwaśnik P, Giannopoulos K (2021) Treatment-free remission-a new aim in the treatment of chronic myeloid leukemia. J Pers Med 11:697.
https://doi.org/10.3390/jpm11080697 - Kwaśnik P, Zaleska J, Link-Lenczowska D et al. (2024) High level of CD8+PD-1+ cells in patients with chronic myeloid leukemia who experienced loss of MMR after imatinib discontinuation. Cells 13:723.
https://doi.org/10.3390/CELLS13080723 - Larsen MV, Lundegaard C, Lamberth K et al. (2007) Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8:424.
https://doi.org/10.1186/1471-2105-8-424 - Li S, Yang L, Ding X et al. (2024) USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway. Oncogenesis 13:27.
https://doi.org/10.1038/s41389-024-00528-z - Li Y, Lin C, Schmidt CA (2012) New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int 12:52.
https://doi.org/10.1186/1475-2867-12-52 - Liu C, Lu X, Fang H et al. (2024) Leukemia associated macrophages and neutrophils contribute to immune suppression through PD-L1 and arginase in BCR-ABL1 chronic myeloid leukemia. Blood 144(Supl 1):6573.
https://doi.org/10.1182/blood-2024-208465 - Mahon FX, Réa D, Guilhot J et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035.
https://doi.org/10.1016/S1470-2045(10)70233-3 - Martínez-López J, Mustjoki S, Porkka K et al. (2021) The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. Leuk Lymphoma 62:2040–2043.
https://doi.org/10.1080/10428194.2021.1889536 - Maurer K, Antin JH (2024) The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. Front Immunol 15:1328858.
https://doi.org/10.3389/fimmu.2024.1328858 - Mori S, Vagge E, le Coutre P et al. (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90:910–914.
https://doi.org/10.1002/ajh.24120 - Mumprecht S, Schürch C, Schwaller J et al. (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114:1528–1536.
https://doi.org/10.1182/blood-2008-09-179697 - Mustjoki S, Ekblom M, Arstila TP et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398–1405.
https://doi.org/10.1038/leu.2009.46 - Najima Y, Yoshida C, Iriyama N et al. (2018) Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—the final results of the D-first study. Leuk Res 66:66–72.
https://doi.org/10.1016/j.leukres.2018.01.010 - Narita M, Masuko M, Kurasaki T et al. (2010) WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci 7:72–81.
https://doi.org/10.7150/ijms.7.72 - Nicolini FE, Dulucq S, Guilhot J et al. (2018) The evaluation of residual disease by digital PCR, and TKI duration are critical predictive factors for molecular recurrence after for stopping imatinib first-line in chronic phase CML patients: results of the STIM2 Study. Blood 132(Suppl. 1):462.
https://doi.org/10.1182/blood-2018-99-113029 - Oji Y, Oka Y, Nishida S et al. (2010) WT1 peptide vaccine induces reduction in minimal residual disease in an imatinib-treated CML patient. Eur J Haematol 85:358–360.
https://doi.org/10.1111/j.1600-0609.2010.01497.x - Pan J, Yu H, Guo Z et al. (2018) Emerging role of sperm-associated antigen 9 in tumorigenesis. Biomed Pharmacother 103:1212–1216.
https://doi.org/10.1016/j.biopha.2018.04.168 - Patterson SD, Copland M (2023) The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities. Curr Hematol Malig Rep 18:19–32.
https://doi.org/10.1007/s11899-023-00688-6 - Qazilbash MH, Wieder E, Thall PF et al. (2017) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31:697–704.
https://doi.org/10.1038/LEU.2016.254 - Rammensee H, Bachmann J, Emmerich NP et al. (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219.
https://doi.org/10.1007/s002510050595 - Rea D, Henry G, Khaznadar Z et al. (2017) Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 102:1368–1377.
https://doi.org/10.3324/haematol.2017.165001 - Rezvani K, Grube M, Brenchley JM et al. (2003) Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102:2892–2900.
https://doi.org/10.1182/blood-2003-01-0150 - Rezvani K, Yong AS, Mielke S et al. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111:236–242.
https://doi.org/10.1182/BLOOD-2007-08-108241 - Rojas JM, Knight K, Wang L et al. (2007) Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21:2287–2295.
https://doi.org/10.1038/sj.leu.2404858 - Ross DM, Branford S, Seymour JF et al. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522.
https://doi.org/10.1182/blood-2013-02-483750 - Rossignol A, Levescot A, Jacomet F et al. (2012) Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur J Immunol 42:1870–1875.
https://doi.org/10.1002/eji.201142043 - Saussele S, Richter J, Guilhot J et al. (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747–757.
https://doi.org/10.1016/S1470-2045(18)30192-x - Sehn LH, Alyea EP, Weller E et al. (1999) Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 17:561–568.
https://doi.org/10.1200/JCO.1999.17.2.561 - Sicuranza A, Breccia M, Iuliano F et al. (2025) Therapeutic vaccinations with p210 peptides in imatinib-treated chronic myeloid leukemia patients: 10 years follow-up of GIMEMA CML0206 and SI0207 studies. Vaccines (Basel) 13:419.
https://doi.org/10.3390/vaccines13040419 - Šmahel M (2011) Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immunother 60:1655–1668.
https://doi.org/10.1007/S00262-011-1126-z - Suwabe T, Shibasaki Y, Tamura S et al. (2024) Decade-long WT1-specific CTLs induced by WT1 peptide vaccination. Int J Hematol 119:399–406.
https://doi.org/10.1007/S12185-024-03723-1 - Takahashi M (2015) Long-term molecular remission with an increase of WT1-specific CTLs after cessation of WT1 peptide vaccination in a patient with CML. Ann Oncol 26(Suppl. 2):ii23.
https://doi.org/10.1093/annonc/mdv093.4 - Tanaka A, Nishikawa H, Noguchi S et al. (2020) Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 217:e20191009.
https://doi.org/10.1084/JEM.20191009 - van Rhee F, Lin F, Cullis JO et al. (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377–3383.
https://doi.org/10.1182/blood.v83.11.3377.3377 - Vigón L, Rodríguez-Mora S, Luna A et al. (2020) Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochem Pharmacol 182:114203.
https://doi.org/10.1016/j.bcp.2020.114203 - Vita R, Mahajan S, Overton JA et al. (2019) The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res 47:D339–D343.
https://doi.org/10.1093/nar/gky1006 - Webster JA, Robinson TM, Blackford AL et al. (2021) A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leuk Res 111:106737.
https://doi.org/10.1016/j.leukres.2021.106737 - Xiu M, Bao W, Wang J et al. (2023) High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma. BMC Cancer 23:1105.
https://doi.org/10.1186/s12885-023-11617-4 - Yong AS, Keyvanfar K, Eniafe R et al. (2008) Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22:1721–1727.
https://doi.org/10.1038/leu.2008.161